Table 1 Baseline characteristics of the patients who underwent CMR
All | No new diagnoses group (n = 112) | New diagnoses group (n = 42) | p value | |
|---|---|---|---|---|
Demographics | ||||
Age, years | 72 ± 10 | 73 ± 9 | 72 ± 12 | 0.61 |
Male | 78 (50.6) | 54 (48.2) | 24 (57.1) | 0.32 |
Clinical findings | ||||
Atrial fibrillation | 72 (46.8) | 50 (44.6) | 24 (52.4) | 0.42 |
Heart rate (bpm) | 70 ± 14 | 70 ± 14 | 72 ± 16 | 0.57 |
Systolic blood pressure (mmHg) | 143 ± 25 | 144 ± 25 | 146 ± 26 | 0.61 |
Diastolic blood pressure (mmHg) | 74 ± 12 | 74 ± 12 | 74 ± 13 | 0.99 |
Body mass index (kg/m2) | 34 ± 7 | 34 ± 7 | 33 ± 9 | 0.66 |
NYHA | ||||
I/II | 106 (68.8) | 77 (68.8) | 29 (69.0) | 0.97 |
III/IV | 48 (31.2) | 35 (31.3) | 13 (31.0) | |
Medical History | ||||
Known coronary artery disease | 32 (20.8) | – | – | – |
Hypertension | 139 (90.3) | 111 (89.3) | 39 (92.9) | 0.60 |
Diabetes | 75 (48.7) | 54 (48.2) | 21 (50.0) | 0.88 |
Chronic obstructive pulmonary disease or asthma | 27 (17.5) | 17 (15.2) | 10 (23.8) | 0.21 |
Chest radiography | ||||
Pulmonary edema | 110 (71.4) | 79 (70.5) | 31 (73.8) | 0.69 |
Medication | ||||
Aspirin | 54 (35.1) | 42 (37.5) | 12 (28.6) | 0.30 |
Beta-blocker | 99 (64.3) | 74 (66.1) | 25 (59.5) | 0.45 |
ACEi or ARB | 130 (84.4) | 97 (86.6) | 33 (78.6) | 0.22 |
Statin | 97 (63.0) | 70 (62.5) | 27 (64.3) | 0.84 |
Loop diuretic | 125 (81.2) | 91 (81.3) | 34 (81.0) | 0.97 |
Biochemistry | ||||
Sodium (mmol/L) | 139 ± 3.4 | 139 ± 3.6 | 140 ± 2.6 | 0.39 |
Urea (mmol/L) | 8.7 ± 3.8 | 8.8 ± 4.0 | 8.3 ± 3.5 | 0.46 |
eGFR (ml/min per 1.73m2) | 66 ± 19 | 66 ± 19 | 64 ± 19 | 0.46 |
BNP (ng/L, median, IQR) | 145 (66–259) | 134 ± (57.5–251) | 175 ± (111–263) | *0.12 |
CMR | ||||
LVEF (%) | 57 ± 6 | 57 ± 6 | 57 ± 7 | 0.98 |
LVEDVI (ml/m2) | 74 ± 18 | 73 ± 17 | 77 ± 21 | 0.26 |
LVESVI (ml/m2) | 33 ± 11 | 32 ± 10 | 34 ± 13 | 0.30 |